EpCAM/TROP1 Antibody (60N5D8) [Janelia Fluor® 635]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-22381JF635
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot
Label
Janelia Fluor 635
Antibody Source
Monoclonal Mouse IgG2b Kappa Clone # 60N5D8
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for EpCAM/TROP1 Antibody (60N5D8) [Janelia Fluor® 635]
Immunogen
Synthetic peptide made to an internal portion of the human EpCAM/TROP1 protein (between amino acids 289-314) [UniProt P16422]
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2b Kappa
Applications for EpCAM/TROP1 Antibody (60N5D8) [Janelia Fluor® 635]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: EpCAM/TROP1
EpCAM functions as an intracellular signaling molecule and contributes to regulation of epithelial-to-mesenchymal (EMT) transition (4,5). EpCAM is cleaved during the process of regulated intramembrane proteolysis (RIP) (4,5). Initial cleavage occurs at the membrane via a disintegrin and metalloprotease 17 (ADAM17) which releases EpCAM's extracellular domain (EpEx) (4,5). A secondary cleavage is mediated by presenilin 2 (PSEN2) which releases EpCAM's cytoplasmic trail (EpICD) (4,5). EpICD translocates to the nucleus where it associates with beta-catenin, FHL-2, and LEF-1 and induces transcription of genes related to EMT and tumor growth (4,5). EpCAM has also been shown to regulate structure and functionality of the apical junction complex of cells through direct interaction with claudin-7 and association with E-cadherin (2,5). Loss of EpCAM disrupts adherins junction and tight junction structure and function (2).
References
1. Mohtar MA, Syafruddin SE, Nasir SN, Low TY. Revisiting the Roles of Pro-Metastatic EpCAM in Cancer. Biomolecules. 2020; 10(2):255. https://doi.org/10.3390/biom10020255
2. Huang L, Yang Y, Yang F, et al. Functions of EpCAM in physiological processes and diseases (Review). Int J Mol Med. 2018; 42(4):1771-1785. https://doi.org/10.3892/ijmm.2018.3764
3. Brown TC, Sankpal NV, Gillanders WE. Functional Implications of the Dynamic Regulation of EpCAM during Epithelial-to-Mesenchymal Transition. Biomolecules. 2021; 11(7):956. https://doi.org/10.3390/biom11070956
4. Uniprot (P16422)
5. Schnell U, Cirulli V, Giepmans BN. EpCAM: structure and function in health and disease. Biochim Biophys Acta. 2013; 1828(8):1989-2001. https://doi.org/10.1016/j.bbamem.2013.04.018
Long Name
Epithelial Cell Adhesion Molecule
Alternate Names
17-1A, CD326, GA733-2, gp40, KS1/4, M4S1, TACSTD1, TROP1
Gene Symbol
EPCAM
Additional EpCAM/TROP1 Products
Product Documents for EpCAM/TROP1 Antibody (60N5D8) [Janelia Fluor® 635]
Product Specific Notices for EpCAM/TROP1 Antibody (60N5D8) [Janelia Fluor® 635]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...